Early this year, retired gynecologist Saul Berg of Fox Chapel stopped by his local pharmacy to pick up two prescription drugs — fluorouracil and imiquimod, which are topical creams for treating skin lesions caused by sun damage.
To his surprise, the pharmacist told him the charge would be $100 per drug for a two-week supply instead of the $12-$14 co-payment he had paid for years.
Co-payments can go up or down for any number of reasons. He knew that. But in this case, the pharmacist’s explanation baffled him.
“He told me that the co-payment would now be a Tier 3, as opposed to Tier 1,” Dr. Berg recalled.
For those unfamiliar with the terms, Medicare Part D prescription drug plans typically organize medications by tiers. Co-payments increase in higher numbered tiers up to Tier 5 specialty drugs.
Historically, generic medications — medications for which the manufacturer’s patent has lapsed, allowing competing drug makers to begin producing it, too — would be classified in lower-cost Tier 1 (preferred generic) or Tier 2 (non-preferred), while Tier 3 would include preferred brand-name drugs in a plan’s formulary.
Where Tier 1 generics may carry a co-payment of a few dollars, or no cost at all, a Tier 2 might range up to $50 or so, a Tier 3 co-payment might double that, and Tiers 4 and 5 often are based on a percentage of the drug’s retail price.

Beginning this year, the Centers for Medicare and Medicaid Services has told insurers that formularies may include both generic and brand name drugs in a higher tier — citing “our continued efforts to provide tier label options that provide flexibility and transparency in benefit design.”
What Dr. Berg knows was that he is paying much more than he used to for generic drugs that have been around for decades.“I can afford Tier 3 prescriptions. That’s not the point,” he said. “I think people ought to know what’s going on.”
What’s going on is “generics are not behaving like generics anymore,” said Leigh Purvis, the Washington, D.C.-based director of health services research for senior advocacy group AARP.
Generic medications are getting more expensive in some cases for reasons ranging from reduced competition because of consolidation in the generic manufacturing sector, to limited supplies of necessary ingredients. Besides pushing up the immediate out-of-pocket cash layout for Medicare recipients, the higher costs move them more quickly to the “donut hole” coverage gap — the gap between the end of a basic benefit and the start of catastrophic coverage during which seniors pay a larger share.
Ms. Purvis noted, though, that generics can also face downward price pressure if additional competitors join the market or if an insurer strikes a special deal with a manufacturer.
“There’s a lot of negotiations taking place behind the scenes.” In the meantime, her strong recommendation is that beneficiaries carefully check their plan’s formulary before renewing — to make sure both that their medications are included and that those medications have not been moved to a higher tier.
An August 2016 report by the U.S. Government Accountability Office found that generic drug prices had fallen 59 percent between 2010 and 2015, but the savings had tapered in recent years.
The reason: In reviewing 1,441 established generic drugs, the report found 315 that at least doubled in cost between 2010 and 2015, with competition — or lack of it — considered the primary driver.
A 2015 Elsevier Clinical Solutions survey of health plans, pharmacy benefit managers, manufacturers and health providers backs that up. More than 75 percent of the survey respondents cited consolidation of manufacturers as either the first or second most likely cause for price increases.
Dr. Berg acknowledges his own error in not checking the printed UPMC for Life printed formulary for 2017, which clearly labels fluorouracil and imiquimod as Tier 3 medications.
Nearly five months after that stop at the pharmacy, Dr. Berg said he still is trying to get a clear explanation for the tier jump — particularly because UPMC’s commercial and marketplace plans still classify both medications as Tier 1 drugs.
“They are discriminating only against Medicare patients,” he said.
Chronis Manolis, UPMC Health Plan’s chief pharmacy officer, said he could not discuss any individual beneficiary’s situation, but cautioned against looking at one or two drugs in isolation. Some drugs move into lower cost categories, too.
“There are hundreds of drugs that we’ve moved from Tier 3 to Tier 1,” he said. Commercial and Medicare formularies may not even have the same number of tiers, and market changes can prompt plans “to look at drugs and tier them differently,” he said.
“We go through a fairly rigorous process with our physicians and talk about the options.” The goal, he added, “is to make sure that we provide the best access and value for our membership.”
Dr. Berg, unlike most Medicare beneficiaries, comes armed with a strong knowledge of fluorouracil and imiquimod.
“Both of those drugs are generic. Both of those are old drugs. Neither of those had an alternative in Tier 1.”
After he filed grievances with UPMC, he says the plan has added Tier 1 alternatives, but both come in a solution form with warnings not to apply near the eyes. Because Dr. Berg uses the drug for a spot near his eyebrow, he cannot safely use the liquid form. In such cases, a patient or physician can request the insurer make an exception to the tier structure or formulary.
Dr. Berg also has filed an appeal to the independent firm that handles complaints to the Centers for Medicare and Medicaid Services, and he is determined to keep pressing for answers.
“I’d like to know, who are the people who make these decisions?”
For him, the tier change has meant a couple hundred dollars out of his pocket each month. “But there are a lot of people on 10-15 medications,” he said.
And if their co-payments increase too much, he said, “They stop taking the drug, or they only take it every 2-3 days. Or they choose between filling the prescription and buying food.”
Steve Twedt: stwedt@post-gazette.com or 412-263-1963.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.